NO20060654L - PPAR-aktiverende forbindelse og farmasoytisk blanding inneholdende samme - Google Patents
PPAR-aktiverende forbindelse og farmasoytisk blanding inneholdende sammeInfo
- Publication number
- NO20060654L NO20060654L NO20060654A NO20060654A NO20060654L NO 20060654 L NO20060654 L NO 20060654L NO 20060654 A NO20060654 A NO 20060654A NO 20060654 A NO20060654 A NO 20060654A NO 20060654 L NO20060654 L NO 20060654L
- Authority
- NO
- Norway
- Prior art keywords
- same
- group
- pharmaceutical composition
- composition containing
- activating compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 230000003213 activating effect Effects 0.000 title abstract 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 title 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 2
- 102000023984 PPAR alpha Human genes 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 abstract 1
- 229940126585 therapeutic drug Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Det er beskrevet en forbindelse for selektiv aktivering av PPARa som er representert ved den generelle formel (1) (hvor R, og R2, som kan være like eller forskjellige, representerer et hydrogenatom eller lignende; R3a, R3b, R4a og R4b, kan være like eller forskjellige, og representerer et hydrogenatom eller lignende; X representerer et oksygenatom eller lignende; Y representerer et oksygenatom, S(O)i (I er tallene 0 til 2), en karbonylgruppe, en karbonylaminogruppe, en aminokarbonylgruppe, en sulfonylaminogruppe eller en NH-gruppe; Z representerer CH eller lignende; n er tallene 1 til 6; og m er tallene 2 til 6) eller et salt derav. Det er også beskrevet et terapeutisk medikament inneholdende en slik forbindelse.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US49935703P | 2003-09-03 | 2003-09-03 | |
| JP2003317353 | 2003-09-09 | ||
| JP2003364817 | 2003-10-24 | ||
| PCT/JP2004/012750 WO2005023777A1 (ja) | 2003-09-03 | 2004-09-02 | Ppar活性化化合物及びこれを含有する医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20060654L true NO20060654L (no) | 2006-04-26 |
| NO335823B1 NO335823B1 (no) | 2015-02-23 |
Family
ID=34279568
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20060654A NO335823B1 (no) | 2003-09-03 | 2006-02-09 | PPAR-aktiverende forbindelse samt anvendelse derav, og terapeutisk medikament inneholdende samme |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US7109226B2 (no) |
| EP (1) | EP1661890B1 (no) |
| JP (2) | JP4226005B2 (no) |
| KR (1) | KR101160808B1 (no) |
| AU (1) | AU2004270538C1 (no) |
| BR (1) | BRPI0413991B8 (no) |
| CA (1) | CA2535749C (no) |
| CY (1) | CY1111867T1 (no) |
| EA (1) | EA009374B1 (no) |
| HR (1) | HRP20110009T1 (no) |
| IL (1) | IL173639A (no) |
| MX (1) | MXPA06002435A (no) |
| NO (1) | NO335823B1 (no) |
| NZ (1) | NZ545692A (no) |
| PL (1) | PL1661890T3 (no) |
| TW (1) | TWI324599B (no) |
| WO (1) | WO2005023777A1 (no) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7521420B2 (en) | 2003-06-18 | 2009-04-21 | Tranzyme Pharma, Inc. | Macrocyclic antagonists of the motilin receptor |
| ATE490264T1 (de) * | 2003-07-31 | 2010-12-15 | Tranzyme Pharma Inc | Räumlich definierte makrocyclische verbindungen, die sich für die entdeckung von arzneimittel eignen |
| US7398116B2 (en) | 2003-08-11 | 2008-07-08 | Veran Medical Technologies, Inc. | Methods, apparatuses, and systems useful in conducting image guided interventions |
| US7301033B2 (en) * | 2005-01-27 | 2007-11-27 | Kowa Co., Ltd. | PPAR-activating compound |
| JP4871259B2 (ja) * | 2005-02-23 | 2012-02-08 | 興和株式会社 | 光学活性ｐｐａｒ活性化化合物及びその製造中間体の製造法 |
| WO2006093142A1 (ja) * | 2005-03-01 | 2006-09-08 | Kowa Co., Ltd. | 光学活性ｐｐａｒ活性化化合物中間体及びその製造法 |
| US7714141B2 (en) | 2005-05-31 | 2010-05-11 | Kowa Co., Ltd. | Processes for production of optically active PPAR-activating compounds and intermediates for production thereof |
| US7767845B2 (en) | 2005-07-28 | 2010-08-03 | Kowa Co., Ltd. | Process for producing optically active 2-hydroxybutyric ester |
| US8088733B2 (en) * | 2006-07-06 | 2012-01-03 | Tranzyme Pharma Inc. | Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders |
| US20100183696A1 (en) * | 2007-01-30 | 2010-07-22 | Allergan, Inc | Treating Ocular Diseases Using Peroxisome Proliferator-Activated Receptor Delta Antagonists |
| TWI407955B (zh) * | 2007-03-29 | 2013-09-11 | Kowa Co | 高脂血症之預防及／或治療劑 |
| US20120165377A1 (en) * | 2009-09-28 | 2012-06-28 | Kowa Co., Ltd. | Agent for reducing visceral fat weight |
| TWI425948B (zh) * | 2012-01-20 | 2014-02-11 | 優生生物科技股份有限公司 | Compositions for the inhibition or killing of Porphyromonas gingivalis and their use for the alleviation or treatment of periodontal disease and other diseases |
| ES2752039T3 (es) | 2012-09-27 | 2020-04-02 | Kowa Co | Agente terapéutico para la dislipidemia |
| CN105102415B (zh) * | 2013-03-29 | 2017-03-15 | 兴和株式会社 | 2‑羟基羧酸或其衍生物的光学纯度提高法 |
| TWI696462B (zh) | 2013-07-10 | 2020-06-21 | 日商興和股份有限公司 | 非酒精性脂肪性肝疾病治療劑 |
| MY182468A (en) | 2013-08-28 | 2021-01-25 | Kowa Co | Therapeutic agent for dyslipidemia |
| US10669296B2 (en) * | 2014-01-10 | 2020-06-02 | Rgenix, Inc. | LXR agonists and uses thereof |
| TW201618777A (zh) * | 2014-09-26 | 2016-06-01 | 興和股份有限公司 | 脂質異常症治療劑 |
| TWI691331B (zh) * | 2014-09-26 | 2020-04-21 | 日商興和股份有限公司 | 脂質異常症治療劑 |
| JP6850730B2 (ja) * | 2015-11-12 | 2021-03-31 | 学校法人 聖マリアンナ医科大学 | 緑内障予防治療剤 |
| DK3275438T3 (da) | 2016-07-29 | 2021-01-18 | Kowa Co | Fremgangsmåder til forebyggelse af hjerte-kar-hændelser hos dyslipidæmiske populationer med fortsat risiko |
| KR102671944B1 (ko) * | 2016-08-25 | 2024-06-03 | 코와 가부시키가이샤 | Pbc 의 치료제 |
| JP2019059673A (ja) * | 2016-08-25 | 2019-04-18 | 興和株式会社 | Ｐｂｃの治療剤 |
| WO2018131626A1 (ja) | 2017-01-11 | 2018-07-19 | 興和株式会社 | 非アルコール性脂肪性肝疾患の予防及び治療薬 |
| US10314825B2 (en) | 2017-02-24 | 2019-06-11 | Kowa Company, Ltd. | Agent for treatment of PBC |
| EP4696381A3 (en) | 2017-06-30 | 2026-04-22 | Kowa Company, Ltd. | Medicine |
| JP6959049B2 (ja) * | 2017-06-30 | 2021-11-02 | 興和株式会社 | 新規低アルブミン血症改善薬 |
| WO2019004453A1 (ja) | 2017-06-30 | 2019-01-03 | 興和株式会社 | 医薬品 |
| JP7007379B2 (ja) * | 2017-06-30 | 2022-02-10 | 興和株式会社 | 医薬組成物 |
| JP7402687B2 (ja) | 2017-06-30 | 2023-12-21 | 興和株式会社 | 医薬組成物 |
| US11298340B2 (en) * | 2017-06-30 | 2022-04-12 | Kowa Company, Ltd. | Pharmaceutical composition |
| US11419854B2 (en) | 2017-06-30 | 2022-08-23 | Kowa Company, Ltd. | Medicament containing pemafibrate |
| HRP20241476T1 (hr) * | 2017-06-30 | 2025-01-03 | Kowa Company, Ltd. | Farmaceutski pripravak |
| US11759456B2 (en) | 2017-06-30 | 2023-09-19 | Kowa Company, Ltd. | Pharmaceutical composition |
| WO2019004447A1 (ja) * | 2017-06-30 | 2019-01-03 | 興和株式会社 | 医薬組成物 |
| EP3713575A4 (en) | 2017-11-21 | 2021-08-25 | Rgenix, Inc. | POLYMORPHS AND THEIR USES |
| JP2021506907A (ja) * | 2017-12-21 | 2021-02-22 | 興和株式会社 | 高トリグリセライド血症の治療方法 |
| US11446282B2 (en) | 2017-12-21 | 2022-09-20 | Kowa Company, Ltd. | Methods of treating mixed dyslipidemia and hypertriglycertdemia |
| US11420945B2 (en) | 2017-12-27 | 2022-08-23 | Teva Pharmaceuticals International Gmbh | Solid state forms of Pemafibrate |
| EP3791874B1 (en) | 2018-05-08 | 2025-12-24 | National University Corporation Okayama University | Pemafibrate and pitavastatin for use in reducing hypertension as a major risk factor for cardiovascular diseases |
| TWI891619B (zh) | 2018-12-27 | 2025-08-01 | 日商興和股份有限公司 | 醫藥品 |
| JP7058763B2 (ja) * | 2018-12-27 | 2022-04-22 | 興和株式会社 | 医薬品 |
| JP2020105174A (ja) * | 2018-12-27 | 2020-07-09 | 興和株式会社 | 医薬組成物 |
| US20220096443A1 (en) * | 2018-12-27 | 2022-03-31 | Kowa Company, Ltd. | Pharmaceutical composition |
| HUE067466T2 (hu) | 2019-12-13 | 2024-10-28 | Inspirna Inc | Fémsók és alkalmazásuk |
| KR20230172463A (ko) | 2021-04-20 | 2023-12-22 | 교와 가부시키가이샤 | 이상지질혈증 또는 심장혈관병의 예방ㆍ치료를 위한 복합 의약 |
| EP4331583A4 (en) * | 2021-04-28 | 2025-04-09 | Kowa Company, Ltd. | Blood carnitine increasing agent |
| US20250221965A1 (en) | 2022-03-31 | 2025-07-10 | The Jikei University | Therapeutic agent for respiratory disease |
| WO2024010030A1 (ja) | 2022-07-06 | 2024-01-11 | 興和株式会社 | 血中マイオスタチン低下剤 |
| EP4556006A4 (en) | 2022-07-15 | 2026-01-07 | Kowa Co | MEDICATION TO LOWER LDL CHOLESTEROL IN THE BLOOD |
| WO2024201358A1 (en) * | 2023-03-31 | 2024-10-03 | Ami Lifesciences Private Limited | A process for the preparation of pemafibrate and intermediates thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS593465B2 (ja) * | 1974-06-04 | 1984-01-24 | 藤沢薬品工業株式会社 | チカンアミノアルキルチカンフエノキシカルボンサンルイノ セイゾウホウ |
| JPS6025425B2 (ja) * | 1975-03-06 | 1985-06-18 | 藤沢薬品工業株式会社 | 置換フエノキシ脂肪酸類の合成法 |
| AU1856997A (en) | 1996-02-02 | 1997-08-22 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
| WO2002046176A1 (en) * | 2000-12-05 | 2002-06-13 | Nippon Chemiphar Co., Ltd. | Ppar (peroxisome proliferator activated receptor) activators |
| DE10151390A1 (de) * | 2001-10-18 | 2003-05-08 | Bayer Ag | Essigsäurederivate |
| US7319104B2 (en) * | 2002-03-01 | 2008-01-15 | Smithkline Beecham Corporation | hPPARs activators |
| US6653334B1 (en) * | 2002-12-27 | 2003-11-25 | Kowa Co., Ltd. | Benzoxazole compound and pharmaceutical composition containing the same |
-
2004
- 2004-09-02 EA EA200600527A patent/EA009374B1/ru not_active IP Right Cessation
- 2004-09-02 BR BRPI0413991A patent/BRPI0413991B8/pt not_active IP Right Cessation
- 2004-09-02 MX MXPA06002435A patent/MXPA06002435A/es active IP Right Grant
- 2004-09-02 PL PL04772699T patent/PL1661890T3/pl unknown
- 2004-09-02 HR HR20110009T patent/HRP20110009T1/hr unknown
- 2004-09-02 CA CA2535749A patent/CA2535749C/en not_active Expired - Fee Related
- 2004-09-02 AU AU2004270538A patent/AU2004270538C1/en not_active Ceased
- 2004-09-02 KR KR1020067003950A patent/KR101160808B1/ko not_active Expired - Fee Related
- 2004-09-02 NZ NZ545692A patent/NZ545692A/xx not_active IP Right Cessation
- 2004-09-02 WO PCT/JP2004/012750 patent/WO2005023777A1/ja not_active Ceased
- 2004-09-02 JP JP2005513668A patent/JP4226005B2/ja not_active Expired - Lifetime
- 2004-09-02 EP EP04772699A patent/EP1661890B1/en not_active Expired - Lifetime
- 2004-09-03 TW TW093126702A patent/TWI324599B/zh not_active IP Right Cessation
- 2004-09-03 US US10/933,467 patent/US7109226B2/en not_active Expired - Lifetime
-
2006
- 2006-02-09 NO NO20060654A patent/NO335823B1/no not_active IP Right Cessation
- 2006-02-09 IL IL173639A patent/IL173639A/en active IP Right Grant
- 2006-04-20 US US11/407,076 patent/US7183295B2/en not_active Expired - Lifetime
-
2008
- 2008-10-31 JP JP2008281020A patent/JP4931893B2/ja not_active Expired - Fee Related
-
2011
- 2011-03-31 CY CY20111100343T patent/CY1111867T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20060654L (no) | PPAR-aktiverende forbindelse og farmasoytisk blanding inneholdende samme | |
| BG108089A (en) | Pyridine matrix metalloproteinase inhibitors | |
| NO20080789L (no) | 1,4-benzotiazepin 1,1-dioksidderivater, fremgangsmate for fremstilling derav, medikamenter inneholdende denne forbindelsen og anvendelse derav som et hypolipid | |
| DK1246806T3 (da) | Aryl- og heteroarylsubstituerede tetrahydroisoquinoliner og anvendelse deraf til blokering af genoptagelse af norepinefrin, dopsmin og serotonin | |
| NO20083026L (no) | Terapeutisk middel for diabetes | |
| NO20071719L (no) | Pyridylinhibitorer for "hedgehog"-signalisering | |
| NO20070468L (no) | Sammensetninger og fremgangsmater for behandling av dyslipidemi | |
| NO20045369L (no) | Nye, substituerte sulfamatanticonvulsivaderivater | |
| EA200600620A1 (ru) | Набор для ингаляции с ингаляционным порошком, содержащим тиотропий | |
| HUP0302792A2 (hu) | Dipeptidil peptidáz ciklopropil-kondenzált pirrolidin-bázisú inhibitorai és eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények | |
| NO20071233L (no) | Fremgangsmate for a beskytte nyttige planter eller planteformeringsmateriale | |
| NZ536734A (en) | Spiroindolinepiperidine derivatives | |
| NO20011351L (no) | Fremgangsmåte for behandling av diabetes ved anvendelse av en AP2 inhibitor og kombinasjon derav | |
| MX2008000255A (es) | Activadores de urea glucocinasa. | |
| DK1483245T3 (da) | 5-substituerede alkylaminopyrazolderivater som pesticider | |
| NO20070570L (no) | Forbindelser. | |
| WO2005097788A3 (en) | Sulfonamides and uses thereof | |
| NO20060426L (no) | Kannabinoid reseptormodulator | |
| NO20063576L (no) | 1,3-dioksanederivativer og analoge forbindelser for behandling av fedme og diabetes | |
| WO2002092072A3 (en) | Drugs for the treatment of the alzheimer disease | |
| ATE441630T1 (de) | Substituierte cyclopenten-verbindungen | |
| NO20054408D0 (no) | 3(2-fenyl-oksazol-4-yl-metoksy)-cykloheksylmetoksyeddiksyrederivater og lignende forbindelser som PPAR-modulatorer for behandling av type 2 diabetes og arterosklerose | |
| NO20043211L (no) | Imidazo [1,2-a]pyridinderivat | |
| SE0200198D0 (sv) | New use | |
| DE60227421D1 (de) | Rmazeutische zusammensetzung und verwendung davon |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |